Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 9,138 matching trials from the live ClinicalTrials.gov search.
Filters: Rochester, Minnesota Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women

NCT00578981
View directory record Official record
Conditions
Osteoporosis, Bone Loss, Age Related, Postmenopausal Bone Loss, Postmenopausal Osteoporosis
Interventions
Osteoporosis Choice Decision Aid
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 31, 2026, 5:24 PM EDT
Completed Phase 4 Interventional

A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation.

NCT00166400
View directory record Official record
Conditions
Heart Valve Diseases
Interventions
metoprolol succinate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2008 · Synced Oct 31, 2026, 5:24 PM EDT
Recruiting Not applicable Interventional

A 3D-Printed External Breast Prosthesis for the Improvement of Patient-reported Outcomes Among Breast Cancer Patients That Underwent a Mastectomy Without Reconstruction

NCT07047872
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Computer-Aided Diagnosis, Prosthetics Intervention, Questionnaire Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01072630
View directory record Official record
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
46
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 31, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

NCT01735630
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ELND005, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 95 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 31, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Remote Mindfulness-Based Physical Activity Intervention for Postmenopausal Women

NCT05590507
View directory record Official record
Conditions
Postmenopausal
Interventions
Mindfulness Audio Recordings
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 31, 2026, 5:24 PM EDT
Recruiting Phase 4 Interventional

A Study to Investigate the Effects of Opioid Exposure on the Ability of the Diaphragm Muscle

NCT05856136
View directory record Official record
Conditions
Respiratory Function Loss, Respiratory Complication
Interventions
Fentanyl Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 31, 2026, 5:24 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program of Ponatinib

NCT01592136
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Interventions
ponatinib
Drug
Lead sponsor
Ariad Pharmaceuticals
Industry
Eligibility
18 Years and older
U.S. locations
33
States / cities
La Jolla, California • San Marcos, California • Vallejo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 31, 2026, 5:24 PM EDT
Completed Phase 2 Interventional

Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

NCT00117975
View directory record Official record
Conditions
Lymphoma
Interventions
galiximab, rituximab
Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
68
States / cities
Washington D.C., District of Columbia • Fort Lauderdale, Florida • Hollywood, Florida + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 31, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant

NCT01305200
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Mucositis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
supersaturated calcium phosphate rinse, placebo, questionnaire administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 21 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
31
States / cities
Arcadia, California • Duarte, California • Oakland, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 31, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

NCT03496571
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Interventions
AK002, Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 31, 2026, 5:24 PM EDT
Completed No phase listed Observational

Assessment of Cardiac Allograft Vasculopathy With Optical Coherence Tomography

NCT01527344
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 31, 2026, 5:24 PM EDT
Terminated Phase 1 Interventional

Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis

NCT03269409
View directory record Official record
Conditions
Osteonecrosis
Interventions
Lactated Ringers, The Celution 800/GP System (Cytori Therapeutics), Adipose Derived Regenerative Cells (ADRC)
Other · Device · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
22 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 31, 2026, 5:24 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

NCT06868212
View directory record Official record
Conditions
Chronic Spontaneous Urticaria (CSU)
Interventions
Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
121
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS

NCT02017912
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Nurown MSC-NTF cells, Placebo
Biological
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 31, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

Adipose Stem Cells for Traumatic Spinal Cord Injury

NCT03308565
View directory record Official record
Conditions
Spinal Cord Injuries, Paralysis
Interventions
Autologous, Adipose derived Mesenchymal Stem Cells
Biological
Lead sponsor
Mohamad Bydon
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 31, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer

NCT00550836
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
panitumumab, erlotinib hydrochloride, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
262
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 163 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 31, 2026, 5:24 PM EDT
Completed No phase listed Observational

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

NCT00874211
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
assessment of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
3,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
451
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 31, 2026, 5:24 PM EDT
Completed Phase 3 Interventional

Talc in Treating Patients With Malignant Pleural Effusion

NCT00002622
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Talc
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
224
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 174 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 31, 2026, 5:24 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

NCT01272037
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
Interventions
Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
5,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1435
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 5:24 PM EDT
Completed Not applicable Interventional Results available

Lifestyle Program for Obstructive Sleep Apnea With Severe Obesity

NCT05343000
View directory record Official record
Conditions
Obstructive Sleep Apnea, Obesity
Interventions
Home-based pulmonary rehabilitation (PR) system
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 31, 2026, 5:24 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071
View directory record Official record
Conditions
Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
eneboparatide, Placebo
Combination Product
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Torrance, California • Denver, Colorado • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 31, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice

NCT04241796
View directory record Official record
Conditions
Cancer
Interventions
Multi-Cancer Early Detection Test
Device
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
50 Years and older
Enrollment
6,662 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
11
States / cities
Roseville, California • Pensacola, Florida • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 31, 2026, 5:24 PM EDT
Terminated Phase 2 Interventional Results available

BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A

NCT00623727
View directory record Official record
Conditions
Hemophilia A
Interventions
rFVIII-FS/pegylated liposomes (BAY79-4980), rFVIII-FS/WFI (BAY14-2222)
Biological
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 70 Years · Male only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
20
States / cities
Orange, California • Sacramento, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 31, 2026, 5:24 PM EDT